The global HER2 Breast Cancer Test market size was estimated at USD 320.4 Million in 2021 and is expected to surpass around USD 628.1 Million by 2030 and poised to grow at a compound annual growth rate (CAGR) of 6.9% during the forecast period 2022 to 2030.
HER2 Breast Cancer Test Market: Overview
HER2 Breast Cancer Test Market: Key Drivers
Report Scope of the HER2 Breast Cancer Test Market
Report Coverage |
Details |
Market Size |
US$ 628.1 Million by 2030 |
Growth Rate |
CAGR of 6.9% from 2022 to 2030 |
Largest Market |
North America |
Fastest Growing Market |
Asia Pacific |
Base Year |
2021 |
Forecast Period |
2022 to 2030 |
Segments Covered |
Test Type, End-user and Region, |
Companies Mentioned |
Abbott Molecular, Inc., Biogenex Laboratories, Inc., Leica Biosystems, Roche, Agilent Technologies, Mylab Discovery Solutions Pvt. Ltd. |
Telehealth Helps Avoid Delay in Breast Cancer Treatment amid Coronavirus Outbreak
The coronavirus outbreak has affected screening, diagnosis, treatment, and follow-up care for breast cancer. This is why the HER2 breast cancer test market is expanding in a staggered manner during the ongoing pandemic. Many individuals are fearing the contraction of the novel infection, leading to postponement and cancellation of treatments and screening. Nevertheless, telehealth services and mobile apps hold promising potentials to avoid delay in treatment of potential patients.
Since many countries have lifted their stay-at-home orders and allowed businesses to re-open, revenue flow is anticipated to grow in the HER2 breast cancer test market. Healthcare providers are extending their arms to provide essential and critical services to improve the patient quality of life during the ongoing pandemic.
Inaccurate HER2 Test Results with IHC Affect Market Growth
The HER2 breast cancer test market is expected to reach US$ 628.1 Mn by 2030. Immunohistochemistry (IHC) is being publicized as the gold standard for HER2 breast cancer testing. However, it has been found that some HER2 test results may be inaccurate, as different labs have different rules for classifying positive and negative HER2 status. Such findings are anticipated to affect market growth.
Inaccurate HER2 test results may deprive women diagnosed with breast cancer of proper care and treatment. Hence, healthcare providers in the HER2 breast cancer test market are increasing awareness about multiple reviewing of HER2 test results from more than one pathologist to attain certainty in outcomes.
FISH Test V/S IHC Test: Which is Better?
The FISH (Fluorescence In Situ Hybridization) test is not as widely available as compared to IHC. However, it has been found that FISH test in more accurate and reliable than IHC. In many cases, a lab will do the IHC test first and order FISH test only if the IHC results do not clearly show whether the cells are HER2-positive or negative.
The HER2 breast cancer test market is expected to register a CAGR of 6.9% during the forecast period. The growing popularity of FISH test helps to map the genetic material in a person’s cells. This test is used to visualize specific genes or portions of genes.
HER2 Testing Becoming Routine Practice for Newly Diagnosed Breast Cancer
IHC and FISH tests are gaining popularity for proper diagnosis, treatment, and follow-up care for HER2 breast cancer. HER2 testing is becoming a routine practice for newly diagnosed breast cancer in pathology. Bright-field in situ hybridization such as chromogenic in situ hybridization (CISH) has an advantage, since it allows histologic evaluation of tumors, utilizes ordinary microscope, can be fully automated, and leaves permanent signals for archival storage.
The CISH test is emerging as a suitable alternative to FISH test. Such trends are contributing to the growth of the HER2 breast cancer test market. For uniformity in accuracy and reproducibility of HER2 testing in breast cancer, the ASCO (American Society of Clinical Oncology) has released guidelines for the interpretation of HER2 status.
Market Segmentation: HER2 Breast Cancer Test Market
Regional Overview: HER2 Breast Cancer Test Market
Some of the prominent players in the HER2 Breast Cancer Test Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global HER2 Breast Cancer Test market
By Geography
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
Key Points Covered in HER2 Breast Cancer Test Market Study: